Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Gerard Pasterkamp,
• Biomarkers are needed for diagnosis, prediction and assessment of treatment efficacy in cardiovascular diseases.
The session provided insight in the research field of innovation in biomarker discovery.
A nice example of fine-tuning the use of miRNAs in diagnosis of atherosclerotic disease was provided by Manuel Mayr (London, GB). He showed that the use of aspirin or heparin strongly affects miRNA clusters that are associates with platelet activation. When these medications were administered, variability between patients vanished.
M. Ala-Korpela (Oulu, F) discussed the upcoming potential of metabolomics. Large numbers of metabolites can be measured in a standardised fashion using NMR and /or Mass spectrometry (MS). The speaker noted that within 5 years, the field of diagnostics would be dominated by metabolite measurements. This expectation, however, merits careful consideration since NMR and MS are not routinely applied technologies in a daily clinical setting, where there is a more urgent need for point of care tests. In addition, metabolites are strongly influenced by age, gender and other risk factors which may limit general applicability.
The next speaker, J. Tunon Fernandez (Madrid, ES), highlighted the current applications of proteomics technology in the field of cardiovascular disease. Examples were given where the following sample types were successfully analysed: blood cells, plaques, serum/plasma and the secretome. The latter (secretome from lesions in a culture setting) was mainly applied for discovery of plaque based markers.
The final presentation by S. Trimarchi (San Donato Milanese, IT) summarised the use of biomarkers of ascending and descending aneurysm formation.
This was an interesting session highlighting the still existing need for new biomarkers, not just form routine diagnostics but also for stratified applications.
Novel circulating biomarkers predicting atherosclerosis, Science in Practice from early detection to guided treatment
© 2017 European Society of Cardiology. All rights reserved